QuidelOrtho (QDEL) AI Stock Analysis

• Market Cap: $1.80B
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: -3.18%
• EPS Growth: 81.18%
• Country: US
• Employees: 6,600
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.74
• Shares Outstanding: 67,625,870
• 10 Day Avg. Volume: 1,411,761
• 30 Day Avg. Volume: 1,551,454
• PEG Ratio: -0.07
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 64.20
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: 0.21
• Enterprise Value/Gross Profit: 1.54
• Enterprise Value/Ebitda: -0.58
• 1Y Price Target: $44.29
• Price Target Upside: 68.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 47 Neutral
• Price Target: $28.00 ▲(6.34%Upside)

The most significant factors affecting the score are the challenging financial performance and valuation, with recent losses and a negative P/E ratio. Technical indicators reinforce a bearish trend, as the stock trades below key moving averages. However, financial stability improvements and strategic efforts to mitigate headwinds provide some positive outlook.

Positive Factors

China growth prospects

There is an expectation for medium to high single-digit growth in China, indicating positive international prospects.

Cost savings initiatives

The company announced additional cost savings initiatives, which are expected to enhance financial performance.

EBITDA margins

The company's EBITDA margins have improved significantly, showing a 450 basis point increase year-over-year.

Negative Factors

Earnings uncertainty

Estimating the earnings impact from tariffs is extremely challenging, creating uncertainty around profitability estimates.

Revenue expectations

There is a decrease in first-quarter revenue expectations primarily driven by a reduction in COVID and flu revenue.

Tariff exposure

QuidelOrtho faces challenges due to tariff exposure, with a significant portion of revenue coming from China and being subject to U.S. tariffs.

QuidelOrtho Business Overview & Revenue Model

Company Description

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

How the Company Makes Money

QuidelOrtho makes money primarily through the sale of its diagnostic products and solutions. The company's revenue streams are derived from the manufacturing and distribution of rapid diagnostic tests, often used at the point of care, as well as laboratory-based diagnostic systems. These products are sold directly to healthcare providers, laboratories, and clinics, and through a network of distributors. Significant partnerships with healthcare institutions and other industry players enhance market reach and adoption. Additionally, the company may engage in licensing agreements and collaborations that provide ancillary revenue. Factors such as the prevalence of infectious diseases, regulatory approvals, and technological advancements in diagnostic testing significantly influence QuidelOrtho's earnings.

QuidelOrtho Financial Statement Overview

Summary

QuidelOrtho is facing profitability challenges due to recent losses, impacting its income statement score. However, improvements in debt management and cash flow stability suggest potential for financial recovery. Strong gross profit margin and equity ratio are positive indicators amid current difficulties.

Income Statement

The revenue has shown a fluctuating trend with a recent decline in TTM compared to the previous year. Gross profit margin remains relatively strong at 55.94% TTM, but the company is currently experiencing negative net and EBIT margins due to substantial losses, impacting profitability.

Balance Sheet

The debt-to-equity ratio has improved significantly in TTM (0.19) compared to the previous year, indicating better leverage. However, the return on equity is negative due to net losses, while the equity ratio remains stable at 46.38%.

Cash Flow

The company has shown a positive shift in free cash flow in TTM, reflecting improved cash management. The operating cash flow to net income ratio is strong, but overall cash flow performance is affected by past negative free cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.76B	2.78B	3.00B	3.27B	1.70B	1.66B
Gross Profit	1.55B	1.29B	1.49B	1.94B	1.27B	1.35B
EBITDA	160.40M	-1.46B	607.00M	1.09B	955.44M	1.09B
Net Income	-333.70M	-2.05B	-10.10M	548.70M	704.20M	810.29M
Balance Sheet
Total Assets	6.46B	6.42B	8.56B	8.86B	2.43B	1.87B
Cash, Cash Equivalents and Short-Term Investments	127.10M	98.30M	167.30M	345.00M	828.50M	489.94M
Total Debt	557.10M	2.68B	2.61B	2.85B	139.30M	108.50M
Total Liabilities	3.46B	3.44B	3.56B	3.92B	501.00M	538.46M
Stockholders Equity	3.00B	2.98B	5.01B	4.93B	1.93B	1.33B
Cash Flow
Free Cash Flow	30.40M	-112.10M	70.90M	744.40M	513.14M	564.84M
Operating Cash Flow	149.30M	83.00M	280.20M	885.30M	805.87M	629.76M
Investing Cash Flow	-185.90M	-149.90M	-187.60M	-1.64B	-319.53M	-63.32M
Financing Cash Flow	84.90M	48.80M	-265.80M	252.00M	-173.18M	-130.28M

QuidelOrtho Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 26.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QDEL, the sentiment is Negative. The current price of 26.33 is below the 20-day moving average (MA) of 28.52, below the 50-day MA of 29.68, and below the 200-day MA of 36.25, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 39.26 is Neutral, neither overbought nor oversold. The STOCH value of 16.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QDEL.

QuidelOrtho Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	83 Outperform	$40.08B	30.69	25.81%	0.78%	9.54%	37.23%
HAE	79 Outperform	$3.57B	22.39	18.83%	―	3.95%	44.09%
HOLX	70 Outperform	$14.70B	27.85	11.77%	―	1.66%	21.95%
MASI	61 Neutral	$8.75B	116.65	-23.93%	―	-0.12%	-713.82%
RGEN	54 Neutral	$6.85B	―	-1.16%	―	4.88%	-196.93%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
QDEL	47 Neutral	$1.80B	―	-10.59%	―	-3.18%	81.18%

QuidelOrtho Corporate Events

QuidelOrtho Stockholders Approve Equity Plan Changes

At the Annual Meeting, QuidelOrtho‘s stockholders approved significant changes to the company’s equity incentive plan, increasing the number of shares authorized for issuance by 6,200,000 and extending the plan’s term to 2035. Additionally, the stockholders elected eleven directors to the board, approved executive compensation, and ratified KPMG LLP as the independent auditor for the 2025 fiscal year.

The most recent analyst rating on (QDEL) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.